Non-inferior antibody levels for HPV16/18 after extended two-dose schedules compared with a six-month interval: findings of a systematic review and meta-analysis

References

• ICO/IARC. Human papillomavirus and related diseases report. 2019.
   Google Scholar
• WHO. Human papillomavirus vaccines: WHO position paper, October 2014—recommendations. Vaccine [Internet]. 2015;33:4383–84. http://www.ncbi.nlm.nih.gov/pubmed/25510390.
   PubMed Web of Science ®Google Scholar
• De Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e180–90. doi:10.1016/S2214-109X(19)30488-7.
   PubMed Web of Science ®Google Scholar
• Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Benedict Yen TS, Ralston R. Human Papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts downloaded from. J Clin Microbiol. 1995;33:2058–63. doi:10.1128/JCM.33.8.2058-2063.1995.
   PubMed Web of Science ®Google Scholar
• Sturegård E, Johansson H, Ekström J, Hansson B-G, Johnsson A, Gustafsson E, Dillner J, Forslund O. Human papillomavirus typing in reporting of condyloma. Sex Transm Dis. 2013;40:123–29.
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JML, Cummings T, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet Infect Dis. 2019;15:565–80.
   Web of Science ®Google Scholar
• WHO. DRAFT: global strategy towards the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2019.
   Google Scholar
• GSK. Cervarix dosage and administration. Nigeria: GSK group of companies; 2015.
   Google Scholar
• Merck Canada Inc. GARDASIL product monograph. Canada: Merck Canada Inc; 2017.
   Google Scholar
• Merck Sharp & Dohme. Highlights of prescribing information. Merck Sharp and Dohme, USA; 2020.
   Google Scholar
• Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine. 2014;32:320–26. doi:10.1016/j.vaccine.2013.11.070.
   PubMed Web of Science ®Google Scholar
• Feldstein LR, Fox G, Shefer A, Conklin LM, Ward K. School-based delivery of routinely recommended vaccines and opportunities to check vaccination status at school, a global summary, 2008–2017. Vaccine. 2020;38:680–89. doi:10.1016/j.vaccine.2019.10.054.
   PubMed Web of Science ®Google Scholar
• Penny ME, Anaya G, Avila K, Bartolini RM. Challenges in the introduction of nation-wide school-based vaccination against HPV in Peru. Int J Vaccine Res. 2018;4(1):1–9.
   Google Scholar
• Dubé E, Gagnon D, Clément P, Bettinger JA, Comeau JL, Deeks S, Guay M, MacDonald S, MacDonald NE, Mijovic H, et al. Challenges and opportunities of school-based HPV vaccination in Canada. Hum Vaccines Immunother. 2019;15:1650–55. doi:10.1080/21645515.2018.1564440.
   PubMed Web of Science ®Google Scholar
• Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros‐Balta AX, Low N, Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males. Cochrane Database Syst Rev. 2019;CD013479. 2019.
   Google Scholar
• Secor AM, Driver M, Kharono B, Hergott D, Liu G, Barnabas RV, Dull P, Hawes SE, Drain PK. Immunogenicity of alternative dosing schedules for HPV vaccines among adolescent girls and young women: a systematic review and meta-analysis. Vaccines. 2020;8:1–13. doi:10.3390/vaccines8040618.
   Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928–d5928. doi:10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355;i419.
   Google Scholar
• Donken R, Knol MJ, Bogaards JA, Van Der Klis FRM, Meijer CJLM, De Melker HE. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis. J Infect. 2015;71:61–73. doi:10.1016/j.jinf.2015.02.005.
   PubMed Web of Science ®Google Scholar
• Donken R, de Melker HE, Rots NY, Berbers G, Knol MJ. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine. 2015;33:1426–32. doi:10.1016/j.vaccine.2015.01.072.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–26. doi:10.1136/bmj.39489.470347.AD.
   PubMed Web of Science ®Google Scholar
• Puthanakit T, Huang L-M, Chiu C-H, Tang R-B, Schwarz TF, Esposito S, Frenette L, Giaquinto C, McNeil S, Rheault P, et al. Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years. J Infect Dis. 2016;214:525–36. doi:10.1093/infdis/jiw036.
   PubMed Web of Science ®Google Scholar
• Lamb F, Herweijer E, Ploner A, Uhnoo I, Sundström K, Sparén P, Arnheim-Dahlström L. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study. BMJ Open. 2017;7:1–7.
   Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of CervarixTM and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin. 2009;5:705–19. doi:10.4161/hv.5.10.9518.
   PubMed Web of Science ®Google Scholar
• Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, Jan Van Doorn L, Schussler J, Lowy DR, et al. Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial. [accessed 2019 Mar 19]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075614/pdf/djx158.pdf.
   Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule. Hum Vaccin [Internet]. 2011 [accessed 2019 Aug 14];7:1374–86. http://www.ncbi.nlm.nih.gov/pubmed/22048171 .
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NTN, Tsu V, LaMontagne DS. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA [Internet]. 2011 [accessed 2021 Mar 31];305:1424–32. https://jamanetwork.com/ .
   PubMed Web of Science ®Google Scholar
• LaMontagne DS, Thiem VD, Huong VM, Tang Y, Neuzil KM. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis [Internet]. 2013 [accessed 2021 Mar 31];208:1325–34. https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jit363 .
   PubMed Web of Science ®Google Scholar
• Donken R, Dobson SRM, Marty KD, Cook D, Sauvageau C, Gilca V, Dionne M, McNeil S, Krajden M, Money D, et al. Immunogenicity of 2 and 3 doses of the quadrivalent human papillomavirus vaccine up to 120 months postvaccination: follow-up of a randomized clinical trial. Clin Infect Dis [Internet]. 2019 [accessed 2019 Oct 16]. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz887/5564371.
   Web of Science ®Google Scholar
• Iversen O-E Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, Block SL, Skrivanek A, Azurah AGN, Fong SM, Dvorak V, Kim K-H, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys Vs A 3-dose regimen in women. JAMA. 2016;316:2411. doi:10.1001/jama.2016.17615.
   PubMed Web of Science ®Google Scholar
• Dobson SR, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793. doi:10.1001/jama.2013.1625.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931. doi:10.1016/j.vaccine.2007.03.049.
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937–49. doi:10.1016/j.vaccine.2006.06.005.
   PubMed Web of Science ®Google Scholar
• Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV VLP vaccines. Expert Rev Vaccines. 2014;13:1027–38. doi:10.1586/14760584.2014.935767.
   PubMed Web of Science ®Google Scholar
• Brotherton JML. Rationalizing the HPV vaccination schedule: a long road to a worthwhile destination. Papillomavirus Res. 2019;8:100190. doi:10.1016/j.pvr.2019.100190.
   PubMed Web of Science ®Google Scholar
• Whitworth HS, Schiller J, Markowitz LE, Jit M, Brisson M, Simpson E, Watson-Jones D. Continued HPV vaccination in the face of unexpected challenges: a commentary on the rationale for an extended interval two-dose schedule. Vaccine. 2021;39:871–75. doi:10.1016/j.vaccine.2020.12.031.
   PubMed Web of Science ®Google Scholar
• Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health. 2008;43:S5.e1–S5.e62.
   Web of Science ®Google Scholar
• Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen O-E, Sings HL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134:e657–65. doi:10.1542/peds.2013-4144.
   PubMed Web of Science ®Google Scholar
• UNICEF. Human papillomavirus vaccine: supply and demand update. Denmark: UNICEF, 2018.
   Google Scholar
• WHO. Meeting of the strategic advisory group of experts on immunization, October 2019: conclusions and recommendations. Wkly Epidemiol Rec. 2019;94:541–60.
   Google Scholar
• JCVI. Joint committee on vaccination and immunisation: statement on the delivery of the HPV vaccine. GOV.UK. UK; 2020.
   Google Scholar